Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily M Hsieh

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphomaEmily M Hsieh, Rayne H Rouce
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Advances in Pediatrics|June 25, 2019
Gene Therapy: Current Applications and Future PossibilitiesDavid H M Steffin, Emily M Hsieh, Rayne H Rouce
American Journal of Perinatology|December 19, 2013
Medication use in the neonatal intensive care unitEmily M Hsieh, Christoph P Hornik, Reese H Clark, et al.
Transplantation and Cellular Therapy|October 11, 2023
INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent ToxicitiesKevin O McNerney, Emily M Hsieh, Haneen Shalabi, et al.
Blood Advances|May 3, 2024
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J Lamble, Liora M Schultz, Khanh Nguyen, et al.
Transplantation and Cellular Therapy|November 1, 2025
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental GroupCandelaria Deimundo Roura, Persis Amrolia, Marc Ansari, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Blood Advances|July 14, 2022
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M Hsieh, Regina M Myers, Bonnie Yates, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphomaEmily M Hsieh, Rayne H Rouce
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Advances in Pediatrics|June 25, 2019
Gene Therapy: Current Applications and Future PossibilitiesDavid H M Steffin, Emily M Hsieh, Rayne H Rouce
American Journal of Perinatology|December 19, 2013
Medication use in the neonatal intensive care unitEmily M Hsieh, Christoph P Hornik, Reese H Clark, et al.
Transplantation and Cellular Therapy|October 11, 2023
INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent ToxicitiesKevin O McNerney, Emily M Hsieh, Haneen Shalabi, et al.
Blood Advances|May 3, 2024
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J Lamble, Liora M Schultz, Khanh Nguyen, et al.
Transplantation and Cellular Therapy|November 1, 2025
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental GroupCandelaria Deimundo Roura, Persis Amrolia, Marc Ansari, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Blood Advances|July 14, 2022
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M Hsieh, Regina M Myers, Bonnie Yates, et al.
Pageof 2